SANCUSO is appropriate for many
of your patients on chemotherapy

SANCUSO has been studied in prevalent cancers⁵

Head and neck cancers — 108,000 cases per year
Gastrointestinal cancers — 275,000 cases per year
Breast cancer — 194,000 cases per year

And on a small but vulnerable patient segment⁵

Gynecological cancers — 33,000 cases per year

IMPORTANT SAFETY INFORMATION
SANCUSO^® (Granisetron Transdermal System) is indicated for the prevention of nausea and vomiting in patients receiving moderately and/or highly emetogenic chemotherapy regimens of up to 5 consecutive days duration.¹ SANCUSO is contraindicated in patients with known hypersensitivity to granisetron or to any of the components of the patch.¹ Granisetron may mask a progressive ileus and/or gastric distention caused by the underlying condition.¹ Mild application site reactions have occurred; remove the patch if severe reaction or a generalized skin reaction occurs.¹ Patients should avoid direct exposure of application site to natural or artificial sunlight by covering with clothing while wearing the patch and for 10 days after removing it.¹ The most common adverse reaction in patients receiving SANCUSO is constipation (5.4%).¹ SANCUSO contains granisetron.¹ Healthcare professionals should avoid prescribing any additional products that contain granisetron. No clinically relevant drug interactions have been reported in clinical studies with SANCUSO.¹

SANCUSO is appropriate for many of your patients on chemotherapy

SANCUSO has been studied in prevalent cancers5

And on a small but vulnerable patient segment5

SANCUSO is appropriate for many
of your patients on chemotherapy

SANCUSO has been studied in prevalent cancers⁵

And on a small but vulnerable patient segment⁵